Skip to Content
Stock Analyst Update

Merck Reports Mixed Quarter; Stock Looks Undervalued

The wide-moat firm faces market headwinds, but we anticipate its outlook will reverse in 2021.

Mentioned:

Merck (MRK) reported mixed first-quarter results with strong reported sales, but it also lowered full-year earnings guidance by 7% at the midpoint of the new range. We don’t expect any major changes to our fair value estimate, as we believe the weaker 2020 outlook will reverse in 2021 when hospital-administered drugs return to more normal utilization following better controls around the coronavirus. Merck’s reduction in guidance is notable, as most drug companies haven’t lowered 2020 guidance. However, the virus is likely more disruptive to Merck, as the firm generates close to two thirds of its human health business from physician-administered products. Also, Merck is one of the few drug companies with an animal health business (10% of total sales), which is more vulnerable to reduced veterinary and consumption demands because of coronavirus concerns. Despite these headwinds, we continue to view Merck as undervalued, with the market not fully appreciating the firm’s strong immuno-oncology positioning, which also supports its wide moat.

In the quarter, strong sales of cancer drug Keytruda (up 46%) helped lift overall sales by 13%, but we expect an overall slowing in sales for 2020, as coronavirus concerns crowd out doctor-administered treatments, followed by a growth rebound in 2021. Given the severity of underlying diseases such as cancer and the strong benefits of vaccines, we expect a strong rebound for physician-administered drugs for Merck in 2021. In particular, 2021 Keytruda sales in Europe should accelerate based on recent reimbursement approvals in the large indication of first-line non-small-cell lung cancer. The recent Keytruda submission for six-week dosing should help with patients wanting to avoid doctors’ offices and further differentiate the drug from four-week dosing by competing drugs. Also, we expect important Keytruda data from an adjuvant (earlier stage) lung cancer study in 2021 that could expand the market potential by close to 25%.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.